Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Eli Lilly and Company
Marc Ferrante; Geert D'Haens; Vipul Jairath; Silvio Danese; Minhu Chen; Subrata Ghosh; Tadakazu Hisamatsu; Jaroslaw Kierkus; Britta Siegmund; Sonja Michelle Bragg; Wallace Crandall; Frederick Durand; Emily Hon; Zhantao Lin; Michelle Ugolini Lopes; Nathan Morris; Marijana Protic; Hilde Carlier; Bruce E Sands; VIVID Study Group